FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OIVID APPROVAL										
OMB Number:	3235-0287									
Estimated average bu	urden									

hours per response:

0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* SCHLEIFER LEONARD S				2. Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS INC					NC (Ch	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
			11	[REGN]						X Directo	•	X	10% Ow	ner			
(Last) (First) (Middle)												X Officer below)	give title		Other (specification)	pecify	
					3. Date of Earliest Transaction (Month/Day/Year) 12/14/2010					CEO and President							
777 OLD SAW MILL RIVER ROAD					12/14/2010												
(Street)					4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line)						
TARRY	TOWN N	Y	10591						X Form filed by One Reporting Person								
(City)	(S	State)	(Zip)								Form filed by More than One Reporting Person						
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
Date				action 2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8) 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4)			5. Amour Securitie Beneficia Owned F Reported	s For ally (D) ollowing (I) (rm: Direct I or Indirect I (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
						Code	Amoun	t (A) (D)	Price	Transacti (Instr. 3 a							
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) (Month/Day/Year) 3. Transaction Date Execution Date, if any (Month/Day/Year)		Code (ransaction Derivative Securities		Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	e s lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)				
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	on(s)			
Non- Qualified Stock Option (right to buy)	\$30.63	12/14/2010		A		125,000		(1)	12/14/2020	Common Stock	125,000	(2)	125,00	00	D		

Explanation of Responses:

- 1. The stock option award vests in four equal annual installments, commencing one year after the date of grant.
- 2. Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is not applicable in this case.

/s/**Leonard S. Schleifer 12/20/2010

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.